Skip to main content

Table 1 Baseline Patient Characteristics

From: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

 

Rechallenge (n = 128) n(%)

Regorafenib (n = 266) n(%)

p

Age, median (min–max)

 

55 (33–80)

58 (25–84)

.170

Sex

Female

64 (50)

95 (37.8)

.023

Male

64 (50)

156 (62.2)

 

ECOG PS

0/1

115 (89.8)

228 (85.7)

.253

2

13 (10.2)

38 (14.4)

 

Tumor side

Right colon

18 (14.1)

54 (20.4)

.129

Left colon

110 (85.9)

211 (79.6)

 

Metastatic statusa

Metachronous

48 (37.5)

110 (41.4)

.464

Synchronous

80 (62.5)

156 (58.6)

 

Metastatic Sitea

Single Site

88 (73.9)

167 (65.7)

.112

Multiple Sites

31 (26.1)

87 (34.3)

 

Liver Only

Yes

71 (55.5)

157 (59.1)

.503

No

57 (44.5)

109 (40.9)

 

KRAS

Wildtype

71 (55.4)

145(54.5)

.337

Mutant

44 (34.3)

112 (42.1)

 

Missing

13 (10.1)

9 (3.4)

 

NRAS

Wildtype

78 (60.9)

194 (72.9)

.122

Mutant

24 (18.7)

38 (14.2)

 

Missing

26 (20.3)

34 (12.7)

 

BRAF

Wildtype

59 (46)

160 (60.1)

.158

Mutant

7 (5.4)

9 (3.4)

 

Missing

62 (48.4)

97 (36.4)

 

Microsatellite status

MSS

14 (10.9)

43 (16.1)

.279

MSI-high

2 (1.6)

2 (0.75)

 

Missing

112 (87.5)

221 (83.1)

 
  1. ECOG PS Eastern Oncology Group Performance Scale, MSI microsatellite instability, MSS microsatellite stable
  2. aStatus at the time of diagnosis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us